Mr. Lamont M. Fulton is President of Regulatory Direction LLc and has overForty years of Pharmaceutical experience (26 inregulatoryaffairs CMC).Mr. Fulton has had roles as both Manager and Director of Chemistry Manufacturing and Controls (CMC) Regulatory and labeling at both Branded(Merck, SmithKline, Wyeth) and Generic drugs firm (Mylan).
Prior to working as the leader to regulatory affairs departments, Mr. Fulton worked at the FDA as a Chemist reviewer in the center for drugs. While at the FDA, He also worked as anAnalyst in the office of regulatory affairs and international office of policy, dealing with FDA/ICH regulations and guidance for global initiatives.
Mr. Fulton's past experience in government and industry, including his current role as senior consultant, has allowed him the opportunity to develop relationship with various CMC partners(Pfizer, Johnson and Johnson, Bristol Myers Squibb, etc.). It has also afforded his consultancy the chance to assist and manage other multidisciplinary teamsachieve approval fordozens ofNDA's, ANDA's to the FDA, as well as provide help with several successful international drug applicationsto the EMEA, MHLW and ROW.
The blended years of both pharmaceutical quality and regulatory affairs has provided Mr.Fulton with a perspective to determine appropriate filing strategy and provide regulatory impact of changes in postâ??marketing products.
Mr. Fulton has BA degree in Chemistry from Cheyney University of Pennsylvania; where he studied under Dr.Taylor on the nature of terpenes and its various derivative.
Certificate of Pharmaceutical training from University of Maryland school of Pharmacy / FDA program.
Mr. Fulton's affiliations included; GPhA (Generic Pharmaceutical Association), ACS American chemical society) RAP (Regulatory Affairs Professional society), PDA (Parenteral Drug Association); Sigma Xi.